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ABSTRACT
Introduction: Since the first case of Middle East
Respiratory Syndrome coronavirus (MERS-CoV)
infection was reported in 2012, the virus has
infected more than 1300 individuals in 26
countries, and caused more than 480 deaths.
Human-to-human transmission requires close
contact, and has typically occurred in the
healthcare setting. Improved global awareness,
together with improved hygiene practices in
healthcare facilities, has been highlighted as key
strategies in controlling the spread of
MERS-CoV. This study tested the in vitro
efficacy of three formulations of povidone
iodine (PVP-I: 4% PVP-I skin cleanser, 7.5%
PVP-I surgical scrub, and 1% PVP-I
gargle/mouthwash) against a reference virus
(Modified vaccinia virus Ankara, MVA) and
MERS-CoV.
Methods: According to EN14476, a standard
suspension test was used to assess virucidal
activity against MVA and large volume plating
was used for MERS-CoV. All products were
tested under clean (0.3 g/L bovine serum
albumin, BSA) and dirty conditions (3.0 g/L
BSA ? 3.0 mL/L erythrocytes), with application
times of 15, 30, and 60 s for MVA, and 15 s for
MERS-CoV. The products were tested undiluted,
1:10 and 1:100 diluted against MVA, and
undiluted against MERS-CoV.
Results: A reduction in virus titer of C4 log10
(corresponding to an inactivation of C99.99%)
was regarded as evidence of virucidal activity.
This was achieved versus MVA and MERS-CoV,
under both clean and dirty conditions, within
15 s of application of each undiluted PVP-I
product.
Conclusion: These data indicate that
PVP-I-based hand wash products for
potentially contaminated skin, and PVP-I
gargle/mouthwash for reduction of viral load
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INTRODUCTION
Four of the six coronaviruses (CoVs) that have
made the transition from mammalian/avian
hosts to humans are endemic in the human
population, and typically associated with mild,
self-limiting respiratory illness [1]. However, the
remaining two human CoVs cause severe
respiratory syndromes and are associated with
considerable mortality [1]. In 2003, the severe
acute respiratory syndrome (SARS)-CoV caused
a disease outbreak that claimed nearly 800 lives
[2], and for the second consecutive decade this
century, a new human CoV has emerged. The
Middle East Respiratory Syndrome (MERS)-CoV
was first isolated from a 60-year-old man in
Saudi Arabia in June 2012 [3]. Three years later,
it has been responsible for the infection of more
than 1300 individuals in 26 countries, and more
than 480 related deaths [4].
Of all the cases of MERS-CoV reported to
date, three quarters have occurred within the
source country of Saudi Arabia (Table 1) [4].
Aside from a moderate outbreak in the United
Arab Emirates (UAE), travel-associated spread to
other countries in the Middle East, as well as
examples in Europe, North America, Africa and
Asia, has typically resulted in very minimal
local outbreaks. The clear exception to this is
situation in the Republic of Korea, where over
180 cases have been reported, all during 2015
[4]. Infection in the index case followed recent
travel to Saudi Arabia, Qatar, UAE and Bahrain
[5]. An International Health Regulations
Emergency Committee has highlighted five
main factors contributing to the spread of
MERS-CoV in the Republic of Korea [6].
Briefly, these were (1) a lack of awareness
among healthcare workers and the general
public; (2) suboptimal infection prevention
and control measures in hospitals; (3) crowded
emergency rooms and multi-bed hospital
rooms; (4) the practice of patients seeking care
at multiple hospitals; (5) multiple visitors
staying with infected patients in hospital
rooms.
Overall, clinical experience with MERS-CoV
indicates that its spread within the human
population requires close contact; the majority
of cases have resulted from human-to-human
transmission in healthcare settings [7]. There is
good potential for outbreaks to be contained,
given suitable levels of awareness and hygiene.
The latest outbreak in Korea, however, is
testament to the cost of neglecting these basic
requirements. A recent study by our group
demonstrated impressive, rapid virucidal
activity of povidone iodine (PVP-I) against the
Ebola virus (EBOV) [8]. PVP-I was also effective
against the European reference virus (Modified
vaccinia virus Ankara; MVA), which was
determined to be a suitable surrogate test
agent, facilitating the safe testing of the
virucidal activity of antiseptic products against
hazardous pathogens, including enveloped
viruses such as EBOV [8]. PVP-I is a
broad-spectrum antimicrobial, used globally in
the medical field—including the Middle East—
as a disinfectant for skin, hands and mucosal
surfaces as well as for wound treatment and eye
applications [9].
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Table 1 Number of laboratory-conﬁrmed cases of MERS-CoV reported to WHO, by country and year
Country 2012 2013 2014 2015 Total
Middle East
Saudi Arabia 5 136 679 217 1037
United Arab Emirates 0 12 57 7 76
Qatar 0 7 2 4 13
Jordan 2 0 10 0 12
Oman 0 1 1 4 6
Iran 0 0 5 1 6
Kuwait 0 2 1 0 3
Yemen 0 0 1 0 1
Total 7 158 756 233 1154
Southeast Asia
Republic of Korea 0 0 0 185 185
Philippines 0 0 0 2 2
China 0 0 0 1 1
Thailand 0 0 0 1 1
Malaysia 0 0 1 0 1
Total 0 0 1 189 190
Europe
United Kingdom 1 3 0 0 4
Germany 1 1 0 1 3
The Netherlands 0 0 2 0 2
France 0 2 0 0 2
Austria 0 0 1 0 1
Greece 0 0 1 0 1
Italy 0 1 0 0 1
Total 2 7 4 1 14
Mediterranean and Arab countries
Tunisia 0 3 0 0 3
Algeria 0 0 2 0 2
Egypt 0 0 1 0 1
Lebanon 0 0 1 0 1
Turkey 0 0 1 0 1
Total 0 3 5 0 8
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It may be hypothesized that PVP-I would also
demonstrate effective disinfectant properties
against MERS-CoV. The study reported here
evaluated skin cleanser, surgical scrub and
gargle/mouthwash formulations of PVP-I for
virucidal activity against both the reference
virus MVA and MERS-CoV itself.
METHODS
Virucidal Products Tested
Three PVP-I antiseptic products were tested in
this study: 4% PVP-I skin cleanser, 7.5% PVP-I
surgical scrub and 1% PVP-I gargle/mouthwash,
each with the brand name Betadine,
manufactured by Mundipharma (Limburg,
Germany). This article does not contain any
new studies with human or animal subjects
performed by any of the authors.
Propagation of the Test Virus
MVA
Methodology for propagation of MVA was as
described in [8]. Briefly, baby hamster kidney
cells (BHK)-21 cells (cell bank of
Friedrich-Loeffler-Institute, Germany) were
infected with MVA (Institute of Animal
Hygiene and Veterinary Public Health,
University of Leipzig, Germany) and cultured
at 37 C in a humid atmosphere under 5.0%
CO2. The virus was cultivated from confluent
monolayers with a maximum age of 2 days.
MERS-CoV
Cultivation of MERS-CoV was based on the
same overall method as for MVA. The
MERS-CoV, HCoV-EMC/2012 (Erasmus
Medical Center, Rotterdam, The Netherlands)
was used as the test virus. Vero E6 cells
(American Type Culture Collection, ATCC)
were used for virus cultivation and the
suspension test.
Inactivation Assay
Tests were carried out once in accordance with
EN14476:2013/FprA1:2015 at 20 ± 1 C [10].
The test assay comprised 100 lL virus
suspension, 100 lL interfering substance
(clean, 0.3 g/L bovine serum albumin [BSA] or
dirty, 3.0 g/L BSA ? 3.0 mL/L erythrocytes) and
800 lL PVP-I product (undiluted, 1:10 or 1:100
dilution). A virus control mixture was also
assessed using double-distilled water in place
of the test product. After the specified contact
time (15, 30 or 60 s), virucidal activity was
immediately suppressed by dilution with nine
volumes of ice-cold medium (minimal essential
medium ? 2.0% fetal calf serum) and serially
diluted tenfold. Infectivity was determined by
Table 1 continued
Country 2012 2013 2014 2015 Total
North America
United States of America 0 0 2 0 2
Total 0 0 2 0 2
Total 9 168 768 423 1368
Data as of 7 July 2015 [4]
MERS-CoV Middle East respiratory syndrome coronavirus, WHO World Health Organization
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means of end point dilution titration in
microtiter plates. Aliquots of 100 lL from each
dilution were added to six 200 lL samples of
BHK-21 cells. Cultures were examined
microscopically for cytopathic effects (CPE)
after 8 days of inoculation.
The virus titers were determined using the
Spearman–Ka¨rber method [11, 12] and
expressed as tissue culture infectious dose 50%
(TCID50/mL). The virucidal activity was
determined by the difference of the
logarithmic titer of the virus control minus
the logarithmic titer of the test virus (D log10
TCID50/mL). This difference is presented as a
reduction factor (RF) including its 95%
confidence interval (CI). A reduction in virus
titer of C4 log10 (corresponding to an
inactivation of C99.99%) was regarded as
evidence of sufficient virucidal activity. The
calculation was performed according to
EN14476 [10].
Inactivation Assay Using Large Volume
Plating (LVP) Method for Verification
of Concentration–Contact Time Values
with Mers-CoVv
In accordance with EN14476:2013/FprA1:2015,
the inactivation tests were conducted once, at
20 ± 1 C [10]. One part MERS-CoV suspension
(100 lL) was mixed with 100 lL of either 0.3 g/L
BSA (clean conditions) or 3.0 g/L BSA ? 3.0 mL/
L erythrocytes (dirty conditions) as the
interfering substance. The virus–protein
mixture was added to 8 parts (800 lL) of the
undiluted test product. After a contact time of
15 s, 20 lL of the test mixture was added to
99.98 mL ice-cold medium. Aliquots (300lL) of
the diluted sample were then added to 336 wells
containing the indicator cells. The cells were
cultivated for 5 days, and then inspected
microscopically after 3 and 5 days for
virus-induced CPE in cell morphology.
Calculations of viral titer (in cases of no virus
or low viral count) were as detailed in [8].
RESULTS
Determination of the PVP-I Kinetics
in Clean and Dirty Conditions Using MVA
The test concentrations and contact periods
were chosen to observe the point at which each
test preparation produced efficient virus
inactivation. To demonstrate virucidal efficacy,
disinfectant and antiseptic products are
required to produce a log10 reduction in virus
titer of at least 4 [10]. The log10 reduction
factors produced by the test products under
clean and dirty conditions at each time point
are shown in Table 2. With each PVP-I
formulation, log10 reduction in viral titer C4
was demonstrated under clean and dirty
conditions after only 15 s with the undiluted
and 1:10 dilutions (except for
gargle/mouthwash, which, in dirty conditions,
required 30 s of exposure at the 1:10 dilution).
Under both clean and dirty conditions, the
virucidal activity of the PVP-I products varied
with the concentration of available iodine as
follows: scrub, 0.75 g/L[7.5 g/L[0.075 g/L;
cleanser, 0.4 g/L[4.0 g/L[0.04 g/L;
gargle/mouthwash, 1.0 g/L[0.1 g/L[0.01 g/L.
Verification of Concentration–Contact
Time Values with MERS-CoV
The titers of MERS-CoV present in the control
samples ranged from 6.00 to 6.50 log10 TCID50/
mL under clean and dirty conditions.
MERS-CoV viral titers were reduced between
4.30 and 4.97 log10 TCID50/mL after 15 s
(Table 2), which corresponds to a reduction in
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MERS-CoV viral titer of C99.99% for all
products tested.
DISCUSSION
As is the case for Ebola, MERS-CoV is an
enveloped virus with a high biosafety level, for
which there is no vaccination, nor any specific
antiviral treatment [13, 14]. While infection can
remain subclinical—indicating that not all cases
may be reported—MERS-CoV more typically
causes severe respiratory disease. During the
first year following the first reported case,
two-thirds of patients suffered severe disease
[15], and over a third of reported cases to date
have been fatal [4].
Containment of spread has proven
achievable in most cases; thus far, no
sustained human-to-human transmission has
occurred anywhere in the world [4]. However, a
lack of awareness among health care workers
and the general public, coupled with
inadequate prevention and control procedures,
can result in outbreaks based on nosocomial
infection, as recently observed in the Republic
of Korea. Based on the current situation, the
World Health Organization (WHO) has issued a
number of recommendations [4]. Many of these
reflect the lack of understanding of how
humans become infected from animal or
environmental sources, with particular
emphasis on precautions relating to exposure
to camels. The other focus is on ensuring that
health care facilities adopt appropriate measures
to decrease the risk of transmission of the virus
from an infected patient to other patients,
health care workers and visitors.
A practical measure applicable to both of
these issues is the implementation of effective
hand hygiene practice. Standard hand hygiene
includes either washing hands with soap and
water or the use of an alcohol-based hand rub
[16]. Randomized, controlled trial data are
available to support the effectiveness of PVP-I
and alcohol hand rubs over plain soap hand
wash for hand decontamination, based on
post-hygiene colony-forming unit count [17].
In the context of virucidal activity, PVP-I has
demonstrated superiority over ethanol-based
sanitizers in inactivating murine norovirus on
a modified finger pad test [18]. In an evaluation
of the effectiveness of nine different hand
sanitizers against feline calicivirus (a surrogate
for norovirus), antiseptics containing 10% PVP-I
achieved a greater viral reduction rate than any
of the alcohol-based sanitizers, non-alcoholic
sanitizers or antimicrobial soaps [19]. PVP-I has
demonstrated virucidal activity against a range
of enveloped and non-enveloped viruses.
Perhaps most relevant in the context of the
MERS-CoV is the evidence for effective
inactivation of the SARS-CoV to below
detectable levels within 2 min of exposure [20].
Effective hand hygiene is crucial in
minimizing viral transmission from the
contaminated hands of an infected individual,
either through direct person-to-person contact,
or indirectly via contamination of surfaces.
However, respiratory viruses are also subject to
airborne (particles B5 lm in size) or droplet
([5 lm) transmission, in which infected
material is released by the infected individual
breathing, coughing or sneezing [21]. Gargling
represents an effective personal hygiene
measure against airborne/droplet transmission,
as it can reduce the microbe count at the
pharynx [22]. Together with hand washing
and mask use, it has been proposed that
gargling is one of the three major personal
hygiene protection measures against common
airborne and droplet-transmitted infections
[22]. Specialists advise that the criteria for
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selecting mouthwashes should include
effectiveness of the antiseptic agent in killing
pathogens [22]. Given the strong in vitro
virucidal activity of PVP-I demonstrated in this
and other studies, gargling/flushing with PVP-I
may be an effective measure to disrupt the
transmission of respiratory viruses, especially
via airborne/droplet transmission or after
uptake via the mouth (such as when touching
the mouth or food with contaminated hands).
The data reported here indicate rapid
virucidal activity of three formulations of
PVP-I against both MVA and MERS-CoV. The
15-s exposure time was assessed to study the
virucidal kinetics of PVP-I against MVA over
time (the minimum contact time for hygienic
hand rub and hand wash defined in
EN14476:2013 is 30 s [10]), and yet proved
sufficient for all three formulations to be
effective, against both MVA and MERS-CoV.
MERS-CoV is a harmful enveloped virus and
requires high biosafety levels for any
investigation. It is not recommended that
disinfectants are tested using highly
contagious and harmful viruses; thus, model
viruses are used. The CEN/TC 216/WG1
committee, which establishes standardized
European testing methods and requirements
for the antimicrobial efficacy of chemical
disinfectants and antiseptics, recently
implemented the enveloped MVA as the
model virus for the claim ‘virucidal active
against enveloped viruses for hygienic hand
rub and hand wash’. MVA was chosen on the
basis of its low biosafety level, its known
environmental stability and its practicability
for laboratory use [23–25]. On the basis of these
practical safety concerns, our study was
conducted primarily using MVA with
confirmation only in MERS-CoV.
Usually, only low titers of MERS-CoV can be
harvested in cell culture, resulting in a range of
5.00–6.50 log10 TCID50/mL. To demonstrate at
least a 4 log10 reduction in virus titer, it is
necessary for test mixtures containing low virus
titers to undergo detoxification by molecular
sieving, or to use a more sensitive assay such as
LVP [26]. In LVP, a high volume of the lowest
apparently non-cytotoxic dilution of the
inactivation assay test mixture is added to the
detector cell line and the cultures are monitored
for virus-specific effects. Using this method,
larger reductions in virus titer can be shown
even at lower viral loads and contact times as
short as 15 s can be tested, minimizing the
impact of any after effects. LVP offers sufficient
sensitivity for reductions in virus titer to be
detected even using test products that are
highly cytotoxic in cell culture [27].
It should be considered that while the results
of this in vitro analysis are a suitable basis for
predictions about the virucidal efficacy of PVP-I,
they do not provide direct information about
the effectiveness of the products in practice.
However, taken together with: (1) the emphasis
placed by WHO on ensuring suitable levels of
hand hygiene; (2) recommendations for
gargling with antiseptic mouthwash for the
control of common airborne and
droplet-transmitted infections [22]; (3) the fact
that PVP-I is a product already in use and
available within the most affected regions of the
world, these data provide strong rationale for
the use of PVP-I products for the prevention of
infection by MERS-CoV. Improved awareness is
needed in the health care setting to ensure
effective containment of the spread of this often
fatal virus.
CONCLUSION
The outbreak of MERS-CoV in the Republic of
Korea is testament to the ongoing risk of
healthcare-associated transmission, and
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reinforces the need for timely diagnosis and
implementation of prevention and control
measures. The three PVP-I products tested in
this study demonstrated virucidal activity
against MVA and MERS-CoV at room
temperature, within only 15 s of exposure.
This was observed under both clean and dirty
conditions. These data are consistent with those
from other studies demonstrating the excellent
virucidal activity of PVP-I against enveloped
viruses.
The data reported here indicate that
PVP-I-based hand wash products for
potentially contaminated skin, together with
PVP-I gargle/mouthwash for reduction of viral
load in the oral cavity and the oropharynx, may
help to support hygiene measures during
outbreaks of respiratory viruses.
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